| ²é¿´: 4695 | »Ø¸´: 12 | ||||||
³ÕÃÎäìÏæÄ¾³æ (ÖøÃûдÊÖ)
|
[½»Á÷]
2012Äêµ°°×ºÍ¿¹ÌåÀàÒ©ÎïÏúÊÛ¶îÒ»ÀÀ ÒÑÓÐ12È˲ÎÓë
|
|||||
|
1.TNF¿¹Ìå 2012ÄêÏúÊ۶266.8ÒÚÃÀÔª£»2011ÄêÏúÊ۶240.4ÒÚÃÀÔª ÊÊÓ¦Ö¢£ºÀà·çʪÐԹؽÚÑ× £¨1£©°¢´ïľµ¥¿¹(adalimumab)£ºHumira£¬TNF¦Á-µ¥¿¹£¬Abbott/Eisai£¬2012ÄêÏúÊÛ¶î95.34ÒÚÃÀÔª £¨2£©ÒÀÄÇÎ÷ÆÕ(etanercept)£ºEnbrel£¬TNF-µ¥¿¹£¬Amgen/Pfizer/Takeda£¬2012ÄêÏúÊÛ¶î84.06ÒÚÃÀÔª £¨3£©Ó¢ÀûÎôµ¥¿¹(infliximab)£ºRemicade£¬TNF-µ¥¿¹£¬Centocor/Merck/Mitsubishi Tanabe£¬2012ÄêÏúÊÛ¶î74.68ÒÚÃÀÔª £¨4£©¸êÀûľµ¥¿¹(golimumab)£ºSimponi£¬TNF¦Á-µ¥¿¹£¬Merck/Centocor/Mitsubishi Tanabe£¬2012ÄêÏúÊÛ¶î6.54ÒÚÃÀÔª £¨5£©ÈüÍ×Öéµ¥¿¹(certolizumab pegol)£ºCimzia£¬TNF¦Á-µ¥¿¹£¬UCB Pharma£¬2012ÄêÏúÊÛ¶î6.13ÒÚÃÀÔª 2.°©Ö¢¿¹Ìå 2012ÄêÏúÊ۶237.4ÒÚÃÀÔª£»2011ÄêÏúÊ۶213.8ÒÚÃÀÔª ÊÊÓ¦Ö¢£ºÁܰÍÁö¡¢ÈéÏÙ°©¡¢½áÖ±³¦°©¡¢·Î°©¡¢°×Ѫ²¡ £¨1£©ÀûÍ×Îôµ¥¿¹(rituximab)£ºRituxan/MabThera£¬CD20-µ¥¿¹£¬Genentech£¬·Ç»ôÆæ½ðÁܰÍÁö£¬2012ÄêÏúÊÛ¶î71.43ÒÚÃÀÔª £¨2£©ÇúÍ×Öéµ¥¿¹(trastuzumab)£ºHerceptin£¬HER2-µ¥¿¹£¬Genentech£¬HER2ÑôÐÔÈéÏÙ°©£¬2012ÄêÏúÊÛ¶î62.72ÒÚÃÀÔª £¨3£©±´·¥µ¥¿¹(bevacizumab)£ºAvastin£¬VEGF-µ¥¿¹£¬Genentech£¬Ö±½á³¦°©¡¢·ÇСϸ°û·Î°©£¬2012ÄêÏúÊÛ¶î61.39ÒÚÃÀÔª £¨4£©Î÷Í×Îôµ¥¿¹(cetuximab)£ºErbitux£¬EGFR-µ¥¿¹£¬Eli Lilly/Bristol-Myers Squibb/Merck Serono£¬Ö±½á³¦°©£¬2012ÄêÏúÊÛ¶î18.74ÒÚÃÀÔª £¨5£©µØÅµµ¥¿¹(denosumab)£ºXgeva£¬RANKL-µ¥¿¹£¬Amgen/Daiichi Sankyo£¬¹Ç°©£¬2012ÄêÏúÊÛ¶î7.48ÒÚÃÀÔª £¨6£©ÒׯÕÀûµ¥¿¹(ipilimumab)£ºYervoy£¬CD152-µ¥¿¹£¬Bristol-Myers Squibb£¬¶à·¢ÐÔ¹ÇËèÁö£¬2012ÄêÏúÊÛ¶î7.48ÒÚÃÀÔª £¨7£©ÅÁÄáµ¥¿¹(panitumumab)£ºVectibix£¬EGFR-µ¥¿¹£¬Takeda/Amgen£¬Ö±½á³¦°©£¬2012ÄêÏúÊÛ¶î5.47ÒÚÃÀÔª £¨8£©SGN-35(brentuximab vedotin)£ºAdcetris£¬CD30-¿¹ÌåżÁªÒ©ÎSeattle Genetics/Takeda£¬»ôÆæ½ðÁܰÍÁö£¬2012ÄêÏúÊÛ¶î1.38ÒÚÃÀÔª £¨9£©°Â·¨Ä¾µ¥¿¹(ofatumumab)£ºArzerra£¬CD20-µ¥¿¹£¬GlaxoSmithKline/Genmab£¬ÂýÐÔÁܰÍϸ°û°×Ѫ²¡£¬2012ÄêÏúÊÛ¶î0.93ÒÚÃÀÔª £¨10£©ÅÁÍ×Öéµ¥¿¹(pertuzumab)£ºPerjeta£¬HER2-µ¥¿¹£¬Genentech£¬HER2ÑôÐÔÈéÏÙ°©£¬2012ÄêÏúÊÛ¶î0.60ÒÚÃÀÔª £¨11£©ÌæÒÁ¹(ibritumomab tiuxetan)£ºZevalin£¬CD20-µ¥¿¹£¬·Ç»ôÆæ½ðÁܰÍÁö£¬2012ÄêÏúÊÛ¶î0.37ÒÚÃÀÔª £¨12£©¿¨Í×Ë÷µ¥¿¹(catumaxomab)£ºRemovab£¬EpCAM/CD3-µ¥¿¹£¬°©ÐÔ¸¹Ë®£¬2012ÄêÏúÊÛ¶î0.05ÒÚÃÀÔª 3.ÒȵºËؼ°ÆäÀàËÆÎï 2012ÄêÏúÊ۶189.2ÒÚÃÀÔª£»2011ÄêÏúÊ۶162.4ÒÚÃÀÔª ÊÊÓ¦Ö¢£ºIÐͺÍIIÐÍÌÇÄò²¡ £¨1£©¸Ê¾«ÒȵºËØ(insulin glargine)£ºLantus£¬³¤Ð§ÒȵºËØ£¬Sanofi£¬2012ÄêÏúÊÛ¶î65.10ÒÚÃÀÔª £¨2£©ÃŶ¬ÒȵºËØ(insulin aspart)£ºNovoLog/NovoRapid£¬ËÙЧÒȵºËØ£¬Novo Nordisk£¬2012ÄêÏúÊÛ¶î29.40ÒÚÃÀÔª £¨3£©Àµ¸¬ÒȵºËØ(insulin lispro)£ºHumalog Mix 50:50 premix£¬Ô¤»ìÒȵºËØ£¬Eli Lilly£¬2012ÄêÏúÊÛ¶î23.96ÒÚÃÀÔª £¨4£©ÖØ×éÈËÒȵºËØ(rhu insulin)£ºActrapid/Novolin£¬¶ÌЧÒȵºËØ£¬Novo Nordisk£¬2012ÄêÏúÊÛ¶î19.90ÒÚÃÀÔª £¨5£©µØÌØÒȵºËØ(insulin detemir)£ºLevemir£¬³¤Ð§ÒȵºËØ£¬Novo Nordisk£¬2012ÄêÏúÊÛ¶î17.23ÒÚÃÀÔª £¨6£©ÃŶ¬ÒȵºËØ(insulin aspart)£ºNovoMix 50£¬Ô¤»ìÒȵºËØ£¬Novo Nordisk£¬2012ÄêÏúÊÛ¶î16.45ÒÚÃÀÔª £¨7£©ÈËÒȵºËØ(human insulin)£ºHumulin 50:50£¬Ô¤»ìÒȵºËØ£¬Eli Lilly£¬2012ÄêÏúÊÛ¶î12.39ÒÚÃÀÔª £¨8£©Àµ¹ÈÒȵºËØ(insulin glulisine)£ºApidra£¬¶ÌЧÒȵºËØ£¬Sanofi£¬2012ÄêÏúÊÛ¶î3.02ÒÚÃÀÔª £¨9£©Insuman Comb/Rapid/Basal/Infusat£ºÖØ×éÈË»ù´¡ÒȵºËØ£¬Sanofi£¬2012ÄêÏúÊÛ¶î1.77ÒÚÃÀÔª 4.Ñ×Ö¢¿¹Ìå 2012ÄêÏúÊ۶73.0ÒÚÃÀÔª£»2011ÄêÏúÊ۶58.3ÒÚÃÀÔª ÊÊÓ¦Ö¢£º¶à·¢ÐÔӲƤ֢¡¢Àà·çʪÐԹؽÚÑס¢¹ýÃôÐÔÏø´¡¢Cryopyrin Ïà¹ØÖÜÆÚÐÔ×ÛºÏÕ÷¡¢Å£Æ¤Ñ¢ £¨1£©ÄÇËûÖéµ¥¿¹(natalizumab)£ºTysabri/Antegren£¬¦Á4/¦Â1/7ÕûºÏËØ-µ¥¿¹£¬Biogen Idec/Elan£¬¶à·¢ÐÔӲƤ֢£¬2012ÄêÏúÊÛ¶î16.00ÒÚÃÀÔª £¨2£©°ÂÂíÖéµ¥¿¹(omalizumab)£ºXolair£¬IgE£¬Genentech/Novartis£¬Àà·çʪÐԹؽÚÑ×£¬2012ÄêÏúÊÛ¶î12.55ÒÚÃÀÔª £¨3£©°¢°ÍÎ÷ÆÕ(abatacept)£ºOrencia£¬CD80/CD86-¿¹Ì壬Bristol-Myers Squibb£¬Àà·çʪÐԹؽÚÑ×£¬2012ÄêÏúÊÛ¶î11.76ÒÚÃÀÔª £¨4£©°¬¿â×éµ¥¿¹(eculizumab)£ºSoliris£¬²¹ÌåC5-µ¥¿¹£¬Alexion£¬Õó·¢ÐÔ˯ÃßÐÔѪºìµ°°×ÄòÖ¢£¬2012ÄêÏúÊÛ¶î11.34ÒÚÃÀÔª £¨5£©ÓÅÌØ¿Ëµ¥¿¹(ustekinumab)£ºStelara£¬IL-12/IL-23-µ¥¿¹£¬Johnson & Johnson£¬Å£Æ¤Ñ¢£¬2012ÄêÏúÊÛ¶î10.25ÒÚÃÀÔª £¨6£©ÍÐÖéµ¥¿¹(tocilizumab)£ºRoActemra/Actemra£¬IL-6R-µ¥¿¹£¬Genentech£¬Àà·çʪÐԹؽÚÑ×£¬2012ÄêÏúÊÛ¶î8.97ÒÚÃÀÔª £¨7£©±´Àûµ¥¿¹(belimumab)£ºBenlysta£¬BLyS-µ¥¿¹£¬GlaxoSmithKline£¬ÏµÍ³ÐÔºì°ßÀÇ´¯£¬2012ÄêÏúÊÛ¶î1.09ÒÚÃÀÔª £¨8£©¿¨Äǵ¥¿¹(canakinumab)£ºIlaris£¬IL-1¦Â-µ¥¿¹£¬Novartis£¬Cryopyrinµ°°×Ïà¹Ø×ÛºÏÕ÷£¬2012ÄêÏúÊÛ¶î0.72ÒÚÃÀÔª £¨9£©ÁÐÂåÎ÷ÆÕ(rilonacept)£ºArcalyst£¬IL-1-¿¹Ì壬Regeneron£¬Cryopyrinµ°°×Ïà¹Ø×ÛºÏÕ÷£¬2012ÄêÏúÊÛ¶î0.20ÒÚÃÀÔª £¨10£©±¶ËûÎ÷ÆÕ(belatacept)£ºNulojix£¬CD80/CD86-¿¹Ì壬Bristol-Myers Squibb£¬ÉöÒÆÖ²£¬2012ÄêÏúÊÛ¶î0.11ÒÚÃÀÔª 5.ÖØ×éÄýѪÒò×Ó 2012ÄêÏúÊ۶72.2ÒÚÃÀÔª£»2011ÄêÏúÊ۶68.3ÒÚÃÀÔª ÊÊÓ¦Ö¢£ºÑªÓѲ¡ £¨1£©ÐÁÄýÑªËØ¦Á(octocog alfa)£ºAdvate/Recombinate£¬Baxter Healthcare£¬2012ÄêÏúÊÛ¶î22.34ÒÚÃÀÔª £¨2£©ÖØ×鿹ѪÓѲ¡Òò×Ó(Rec Anti-hemophilic Factor)£ºKogenate FS£¬2012ÄêÏúÊÛ¶î15.51ÒÚÃÀÔª £¨3£©ÒÀËûÄýÑªËØ¦Á(eptacog alfa)£ºNovoseven£¬Novo Nordisk£¬2012ÄêÏúÊÛ¶î15.73ÒÚÃÀÔª £¨4£©ÅµÄÇÄýÑªËØ¦Á(nonacog alfa)£ºBeneFix£¬Pfizer£¬2012ÄêÏúÊÛ¶î7.75ÒÚÃÀÔª £¨5£©ÖØ×éÄýѪÒò×ÓVIII£ºHelixate FS/Helixate NexGen£¬CSL Behring£¬2012ÄêÏúÊÛ¶î5.01ÒÚÃÀÔª £¨6£©ÄªÂÞÄýÑªËØ¦Á(moroctocog alfa)£ºXyntha/Refacto£¬Pfize/Swedish Orphan Biovitrum£¬2012ÄêÏúÊÛ¶î5.84ÒÚÃÀÔª 6.´Ùºìϸ°ûÉú³ÉËØ 2012ÄêÏúÊ۶72.0ÒÚÃÀÔª£»2011ÄêÏúÊ۶81.7ÒÚÃÀÔª ÊÊÓ¦Ö¢£ºÆ¶Ñª £¨1£©°¢·¨´ï±´²´Í¡(darbepoetin alfa)£ºAranesp£¬Amgen£¬2012ÄêÏúÊÛ¶î20.40ÒÚÃÀÔª £¨2£©´ï±´²´Í¡(darbepoetin)£ºNESP£¬Kyowa Hakko Kirin£¬2012ÄêÏúÊÛ¶î5.86ÒÚÃÀÔª £¨3£©°¢·¨ÒÀ²´Í¡(epoetin alfa)£ºEpogen£¬Amgen£¬2012ÄêÏúÊÛ¶î19.41ÒÚÃÀÔª £¨4£©°¢·¨ÒÀ²´Í¡(epoetin alfa)£ºESPO£¬Kyowa Hakko Kirin£¬2012ÄêÏúÊÛ¶î0.39ÒÚÃÀÔª £¨5£©°¢·¨ÒÀ²´Í¡(epoetin alfa)£ºProcrit/Eprex/Erypo£¬Ortho Biotech/Janssen-Cilag£¬2012ÄêÏúÊÛ¶î14.62ÒÚÃÀÔª £¨6£©±¶ËûÒÀ²´Í¡(epoetin beta)£ºNeoRecormon£¬Roche£¬2012ÄêÏúÊÛ¶î5.36ÒÚÃÀÔª £¨7£©±¶ËûÒÀ²´Í¡(epoetin beta)£ºEpogin/Epoch£¬Roche£¬2012ÄêÏúÊÛ¶î1.82ÒÚÃÀÔª £¨8£©¾ÛÒÒ¶þ´¼±¶ËûÒÀ²´Í¡(polyethylene glycol-epoetin beta)£ºMircera/Methoxy£¬Roche£¬2012ÄêÏúÊÛ¶î4.09ÒÚÃÀÔª 7.¸ÉÈÅËØ¦Â 2012ÄêÏúÊ۶71.4ÒÚÃÀÔª£»2011ÄêÏúÊ۶65.7ÒÚÃÀÔª ÊÊÓ¦Ö¢£º¶à·¢ÐÔÓ²»¯Ö¢ £¨1£©¸ÉÈÅËØ¦Â-1a(interferon beta-1a)£ºAvonex£¬Biogen Idec£¬2012ÄêÏúÊÛ¶î29.00ÒÚÃÀÔª £¨2£©¸ÉÈÅËØ¦Â-1a(interferon beta-1a)£ºRebif£¬Merck Serono£¬2012ÄêÏúÊÛ¶î24.83ÒÚÃÀÔª £¨3£©¸ÉÈÅËØ¦Â-1b(interferon beta-1b)£ºBetaferon/Betaseron£¬Bayer£¬2012ÄêÏúÊÛ¶î15.96ÒÚÃÀÔª £¨4£©¸ÉÈÅËØ¦Â-1b(interferon beta-1b)£ºExtavia£¬Novartis£¬2012ÄêÏúÊÛ¶î1.59ÒÚÃÀÔª 8.Á£Ï¸°û¼¯Âä´Ì¼¤Òò×Ó 2012ÄêÏúÊ۶56.3ÒÚÃÀÔª£»2011ÄêÏúÊ۶57.5ÒÚÃÀÔª ÊÊÓ¦Ö¢£º»¯ÁƸ¨ÖúÒ© £¨1£©Åà·Ç¸ñ˾ͤ(pegfilgrastim)£ºNeulasta£¬Amgen£¬2012ÄêÏúÊÛ¶î40.92ÒÚÃÀÔª £¨2£©·Ç¸ñ˾ͤ(filgrastim)£ºNeupogen£¬Amgen£¬2012ÄêÏúÊÛ¶î12.60ÒÚÃÀÔª £¨3£©·Ç¸ñ˾ͤ(filgrastim)£ºGran£¬Kyowa Hakko Kirin£¬2012ÄêÏúÊÛ¶î1.36ÒÚÃÀÔª £¨4£©À´¸ñ˾ͤ(lenograstim)£ºNeutrogin£¬Roche£¬2012ÄêÏúÊÛ¶î1.40ÒÚÃÀÔª 9.ÑÛ¿ÆÓÿ¹Ìå 2012ÄêÏúÊ۶48.3ÒÚÃÀÔª£»2011ÄêÏúÊ۶37.5ÒÚÃÀÔª ÊÊÓ¦Ö¢£ºÊªÐÔÄêÁäÏà¹ØÐԻư߱äÐÔ £¨1£©À×Öéµ¥¿¹(ranibizumab)£ºLucentis£¬VEGF-µ¥¿¹£¬Genentech/Novartis£¬2012ÄêÏúÊÛ¶î39.75ÒÚÃÀÔª £¨2£©°¢°ØÎ÷ÆÕ(aflibercept)£ºEylea£¬VEGF-µ¥¿¹£¬Regeneron/Bayer£¬2012ÄêÏúÊÛ¶î8.57ÒÚÃÀÔª 10.Ã¸Ìæ´úÁÆ·¨ 2012ÄêÏúÊ۶31.9ÒÚÃÀÔª£»2011ÄêÏúÊ۶3.04ÒÚÃÀÔª ÊÊÓ¦Ö¢£ºº±¼û²¡ £¨1£©ÒÁÃ×ÜÕø(imiglucerase)£ºCerezyme£¬Genzyme£¬IÐÍGaucher²¡£¬2012ÄêÏúÊÛ¶î8.30ÒÚÃÀÔª £¨2£©°¢ÆÏÌÇÜÕø¦Á(alglucosidase alpha)£ºLumizyme/Myozyme£¬Genzyme£¬Pompe²¡£¬2012ÄêÏúÊÛ¶î6.06ÒÚÃÀÔª £¨3£©°¬¶ÅÁòø(idursulfase)£ºElaprase£¬Shire/Genzyme£¬IIÐÍð¤¶àÌÇÖü»ýÖ¢£¬2012ÄêÏúÊÛ¶î4.98ÒÚÃÀÔª £¨4£©°¢¼ÓÌÇø¦Á(agalsidase alfa)£ºReplagal£¬Shire/Dainippon Sumitomo£¬Fabry²¡£¬2012ÄêÏúÊÛ¶î4.97ÒÚÃÀÔª £¨5£©¼ÓÁòø(galsulfase)£ºNaglazyme£¬Biomarin/AnGes MG£¬VIÐÍð¤¶àÌÇÔö¶àÖ¢£¬2012ÄêÏúÊÛ¶î2.57ÒÚÃÀÔª £¨6£©°¢¼ÓÌÇø¦Â(agalsidase beta)£ºFabrazyme£¬Genzyme£¬Fabry²¡£¬2012ÄêÏúÊÛ¶î3.83ÒÚÃÀÔª £¨7£©ÀÂÞÄáø(laronidase)£ºAldurazyme£¬Biomarin/Genzyme£¬IÐÍð¤¶àÌÇÔö¶àÖ¢£¬2012ÄêÏúÊÛ¶î1.93ÒÚÃÀÔª £¨8£©ÆÏÌÇÄÔÜÕ֬ø¦Á(velaglucerase alfa)£ºVriv£¬Shire£¬IÐÍGaucher²¡£¬2012ÄêÏúÊÛ¶î3.07ÒÚÃÀÔª 11.ÈËÉú³¤¼¤ËØ 2012ÄêÏúÊ۶29.3ÒÚÃÀÔª£»2011ÄêÏúÊ۶30.3ÒÚÃÀÔª ÊÊÓ¦Ö¢£ºÉú³¤¼¤Ëز»×ã £¨1£©somatropin£ºNorditropin£¬Novo Nordisk£¬2012ÄêÏúÊÛ¶î10.03ÒÚÃÀÔª £¨2£©somatropin£ºGenotropin£¬Pfizer£¬2012ÄêÏúÊÛ¶î8.32ÒÚÃÀÔª £¨3£©somatropin£ºHumatrope£¬Eli Lilly£¬2012ÄêÏúÊÛ¶î3.92ÒÚÃÀÔª £¨4£©somatropin£ºNutropin/Nutropin AQ£¬Genentech£¬2012ÄêÏúÊÛ¶î3.24ÒÚÃÀÔª £¨5£©somatropin£ºSaizen£¬Merck Serono £¬2012ÄêÏúÊÛ¶î3.28ÒÚÃÀÔª 12.¸ÉÈÅËØ¦Á 2012ÄêÏúÊ۶24.1ÒÚÃÀÔª£»2011ÄêÏúÊ۶24.3ÒÚÃÀÔª ÊÊÓ¦Ö¢£º±ûÐ͸ÎÑ× £¨1£©¾ÛÒÒ¶þ´¼¸ÉÈÅËØ¦Á-2a(peginterferon alfa-2a)£ºPegasys£¬Roche£¬HCV¸ÐȾ£¬2012ÄêÏúÊÛ¶î17.55ÒÚÃÀÔª £¨2£©¾ÛÒÒ¶þ´¼¸ÉÈÅËØ¦Á-2b(pegylated interferon alfa-2b)£ºPeg-Intron£¬Merck£¬2012ÄêÏúÊÛ¶î6.53ÒÚÃÀÔª 13.´ÙÂÑÅݼ¤ËØ 2012ÄêÏúÊ۶12.7ÒÚÃÀÔª£»2011ÄêÏúÊ۶12.3ÒÚÃÀÔª ÊÊÓ¦Ö¢£ºÅÅÂÑÕϰ £¨1£©´ÙÂÑÅÝËØ¦Â(follitropin beta)£ºPuregon/Follistim£¬Merck£¬4.68ÒÚÃÀÔª £¨2£©ÖØ×é´ÙÂÑÅÝËØ¦Á(rec follitropin beta)£ºGonal-f£¬Merck Serono£¬8.03ÒÚÃÀÔª 14.²¡¶¾¿¹Ìå 2012ÄêÏúÊ۶10.4ÒÚÃÀÔª£»2011ÄêÏúÊ۶9.8ÒÚÃÀÔª ÊÊÓ¦Ö¢£ººôÎüµÀºÏ°û²¡¶¾¸ÐȾ ÅÁÀûÖéµ¥¿¹(palivizumab)£ºSynagis£¬AstraZeneca£¬2012ÄêÏúÊÛ¶î10.38ÒÚÃÀÔª ÆäËû¿¹Ìå 2012ÄêÏúÊ۶9.8ÒÚÃÀÔª£»2011ÄêÏúÊ۶6.7ÒÚÃÀÔª £¨1£©°¢Îôµ¥¿¹(abciximab)£ºReoPro£¬Eli Lilly/Centocor£¬Ñª¹ÜÊÖÊõ¸¨ÖúÒ©£¬2012ÄêÏúÊÛ¶î1.43ÒÚÃÀÔª £¨2£©µØÅµµ¥¿¹(denosumab)£ºProlia£¬Amgen/Daiichi-Sankyo/GlaxoSmithKline£¬¾¾øÆÚºó¹ÇÖÊÊèËÉ£¬2012ÄêÏúÊÛ¶î4.72ÒÚÃÀÔª £¨3£©ÂÞÃ×˾ͤ(romiplostim)£ºNplate£¬Amgen£¬ÌØ·¢ÐÔѪС°åȱ·¦ÐÔ×ϰßÖ¢£¬2012ÄêÏúÊÛ¶î3.68ÒÚÃÀÔª ÆäËûµ°°× 2012ÄêÏúÊ۶41.4ÒÚÃÀÔª£»2011ÄêÏúÊ۶36.8ÒÚÃÀÔª £¨1£©Èâ¶¾¸Ë¾úËØA(onabotulinumtoxinA)£ºBotox£¬ÃÀÈݳýÖ壬2012ÄêÏúÊÛ¶î17.66ÒÚÃÀÔª £¨2£©ÌæÄÎÌæÆÕø(tenecteplase)£ºTNKase/Metalyse£¬Genentech/Boehringer Ingelheim£¬¼±ÐÔÐ£ËÀ£¬2012ÄêÏúÊÛ¶î6.22ÒÚÃÀÔª £¨3£©°¢·¨Á´µÀø(dornase alfa)£ºPulmozyme£¬Genentech£¬ÄÒÐÔÏËά»¯£¬2012ÄêÏúÊÛ¶î5.72ÒÚÃÀÔª £¨4£©Èâ¶¾¸Ë¾úËØA(abobotulinumtoxinA)£ºIpsen£¬Cervical dystony£¬2012ÄêÏúÊÛ¶î3.10ÒÚÃÀÔª £¨5£©°¢·¨µØ²©ÌØÃ÷(dibotermin alfa)£ºInductOs£¬Pfizer£¬¼±ÐÔëֹǹÇÕÛ£¬2012ÄêÏúÊÛ¶î2.63ÒÚÃÀÔª £¨6£©ÅàάË÷ÃÏ(pegvisomant)£ºSomavert£¬Pfizer£¬Ö«¶Ë·Ê´óÖ¢£¬2012ÄêÏúÊÛ¶î1.97ÒÚÃÀÔª £¨7£©¿ËÁ¢Ëûø(crisantaspase)£ºErwinase£¬Jazz£¬¼±ÐÔÁܰÍϸ°û°×Ѫ²¡£¬2012ÄêÏúÊÛ¶î1.32ÒÚÃÀÔª £¨8£©°¢Äǰ×ÖÍËØ(anakinra)£ºKineret£¬Swedish Orphan Biovitrum£¬Àà·çʪÐԹؽÚÑ×£¬2012ÄêÏúÊÛ¶î0.75ÒÚÃÀÔª £¨9£©ÖØ×éÈËÄýѪø(rhThrombin)£ºRecothrom£¬The Medicines Company/Bristol-Myers Squibb£¬ÊÖÊõֹѪ£¬2012ÄêÏúÊÛ¶î0.67ÒÚÃÀÔª £¨10£©¿¹ÄýѪøIII(antithrombin III)£ºNeuart£¬Mitsubishi/CSL Behring£¬ÃÖÉ¢ÐÔѪ¹ÜÄÚÄýѪ£¬2012ÄêÏúÊÛ¶î0.46ÒÚÃÀÔª £¨11£©°¬¿¨ÀëÄ(ecallantide)£ºKalbitor£¬Dyax/Defiante£¬ÒÅ´«ÐÔѪ¹ÜÐÔË®Ö×£¬2012ÄêÏúÊÛ¶î0.40ÒÚÃÀÔª £¨12£©ÃÀ¿¨ÉáÃ÷(mecasermin)£ºIncrelex£¬Ipsen£¬IGFȱ·¦£¬2012ÄêÏúÊÛ¶î0.37ÒÚÃÀÔª £¨13£©ÅÁÀû·òÃ÷(palifermin)£ºKepivance£¬Swedish Orphan Biovitrum£¬¿ÚǻճĤÑ×£¬2012ÄêÏúÊÛ¶î0.13ÒÚÃÀÔª £¨14£©ÖØ×éÈË͸Ã÷ÖÊËáø(rhu hyaluronidase)£ºHylenex£¬Halozyme£¬Æ¤ÏÂ×¢É丨ÖúÒ©£¬2012ÄêÏúÊÛ¶î0.03ÒÚÃÀÔª 2012Äê×ÜÏúÊ۶1246.2ÒÚÃÀÔª£»2011Äê×ÜÏúÊ۶1129.3ÒÚÃÀÔª Ref: R&D pipeline news. Blockbuster Biologics 2012 [ Last edited by ³ÕÃÎäìÏæ on 2013-5-13 at 20:11 ] |
» ÊÕ¼±¾ÌûµÄÌÔÌûר¼ÍƼö
Ò©Î﹤ÒÕ | ÐÂÒ©¶¯Ì¬ | °ÐµãÒÖÖÆ¼ÁÑз¢½øÕ¹ |
» ±¾ÌûÒÑ»ñµÃµÄºì»¨£¨×îÐÂ10¶ä£©
» ²ÂÄãϲ»¶
¶à¾Û×é°±Ëᣬ´ó·Ö×ÓÁ¿
ÒѾÓÐ657È˻ظ´
ÒȵºËصÄʵÑéÊÒ±í´ï
ÒѾÓÐ0È˻ظ´
Ò©ÎïѧÂÛÎÄÈóÉ«/·ÒëÔõôÊÕ·Ñ?
ÒѾÓÐ89È˻ظ´
ÒȵºËصÄʵÑéÊÒ±í´ï
ÒѾÓÐ0È˻ظ´
ÒȵºËصÄʵÑéÊÒ±í´ï
ÒѾÓÐ0È˻ظ´
ÒȵºËصÄʵÑéÊÒ±í´ï
ÒѾÓÐ1È˻ظ´
ÒȵºËصÄʵÑéÊÒ±í´ï
ÒѾÓÐ0È˻ظ´
ÒȵºËصÄʵÑéÊÒ±í´ï
ÒѾÓÐ0È˻ظ´
ÇóÖúµç×Ӱ棺¾§ÐÍÒ©ÎïÑз¢ÀíÂÛÓëÓ¦ÓÃ
ÒѾÓÐ0È˻ظ´
±±¾©´óѧҩѧԺ³ÏÕÐÒ©Îﻯѧ/Óлú»¯Ñ§·½Ïò²©Ê¿ºó
ÒѾÓÐ5È˻ظ´
» ±¾Ö÷ÌâÏà¹Ø¼ÛÖµÌùÍÆ¼ö£¬¶ÔÄúͬÑùÓаïÖú:
¼±£¡´ý±ÏÒµ£¡Ê¹ÓÃELISA¼ì²âѪÇåÖп¹ÌåµÎ¶È£¬°ü±»Ê±µÄ¿¹Ô¿ÉÒÔ²»ÓëÔØÌåµ°°×żÁªÂð£¿
ÒѾÓÐ14È˻ظ´
ôÈ»ùÓ«¹â΢Çò±ê¼Çµ°°×¿¹Ìå
ÒѾÓÐ22È˻ظ´
ҩѶ2012-12-24
ÒѾÓÐ5È˻ظ´
ÉúÎïÁìÓòÖУ¬³£¼ûÎïÆ·±ÈÈçµ°°×¡¢¿¹Ìå¡¢IgG¡¢ÖÊÁ£¡¢DNA¡¢ÄÚ¶¾ËصȷÖ×ÓÌå»ý´óС
ÒѾÓÐ3È˻ظ´
¿¹ÌåºÍÔØÌåµ°°×ÓнáºÏÂð£¿
ÒѾÓÐ7È˻ظ´
Òª×ö¿¹Ì壬ÈçºÎÑ¡ÔñÓÃÄĶÎÐòÁÐÀ´±í´ïµ°°×£¿
ÒѾÓÐ5È˻ظ´
2011ÄêÑз¢Í¶Èë×î´óµÄ15¼ÒÉúÎï¼¼Êõ¹«Ë¾
ÒѾÓÐ11È˻ظ´
³£¼û¼¸ÖÖÓлúÈܼÁ¶Ô¿¹Ìåµ°°×µÄÓ°Ï죬ÓÐÈË×ܽá¹ýÂð
ÒѾÓÐ3È˻ظ´
³ÏÕÐÓзÖ×ÓÉúÎïѧ¼°µ°°×Öʱí´ï´¿»¯±³¾°µÄ²©Ê¿Ò»Ä꼶ͬѧµ½ÃÀ¹úÀ´×ö¿¹Ìåengineering
ÒѾÓÐ16È˻ظ´
¡¾ÇóÖú/½»Á÷¡¿µ°°×´òÍÃ×Ó×ö¿¹Ìå¶¼ÓÐÄÄЩÐèҪעÒâµÄ£¿
ÒѾÓÐ3È˻ظ´
¡¾ÇóÖú/½»Á÷¡¿¸÷λ´óÏÀ£¬ÎÒµÄÄ¿µÄµ°°×ûÓÐרÃŵĿ¹Ì壬ÈçºÎ¼ì²âËüÔڴ󳦸˾úÖеıí´ï?
ÒѾÓÐ14È˻ظ´
¡¾ÇóÖú/½»Á÷¡¿×î½ü¹ºÂòµÄÓ«¹â±ê¼ÇµÄPÌǵ°°×¿¹ÌåµÄʹÓÃÎÊÌâ
ÒѾÓÐ9È˻ظ´
¡¾ÇóÖú/½»Á÷¡¿¼±ÇóÁ×ËữµÄSmoxµ°°×¿¹ÌåºÍÀ¥³æÏ¸°û×ªÈ¾ÔØÌå
ÒѾÓÐ3È˻ظ´
¡¾ÇóÖú¡¿ÖØ×éÈ˵°°×¿¹ÌåÈçºÎ¼ì²âºÍ¼ì²âÒâÒå
ÒѾÓÐ3È˻ظ´
¹Å¿É¤×
ÈÙÓþ°æÖ÷ (ÎÄ̳¾«Ó¢)
- Ó¦Öú: 91 (³õÖÐÉú)
- ¹ó±ö: 16.835
- ½ð±Ò: 19133.1
- É¢½ð: 40372
- ºì»¨: 275
- ɳ·¢: 183
- Ìû×Ó: 25427
- ÔÚÏß: 1083.6Сʱ
- ³æºÅ: 1034379
- ×¢²á: 2010-06-02
- ÐÔ±ð: GG
- רҵ: Ò©ÎïÉè¼ÆÓëÒ©ÎïÐÅÏ¢
- ¹ÜϽ: µ¼Ê¦ÕÐÉú
¡ï
Сľ³æ: ½ð±Ò+0.5, ¸ø¸öºì°ü£¬Ð»Ð»»ØÌû
Сľ³æ: ½ð±Ò+0.5, ¸ø¸öºì°ü£¬Ð»Ð»»ØÌû
| ÉúÎïÒ©ÕæÇ¿ÊÆ£¬»¯Ò©³ö·ºÎÔÚ£¬ÊÇ·ñÒâζ×Åĩ·ÁË |

2Â¥2013-05-13 21:03:10
kdl0721
½ð³æ (ÖøÃûдÊÖ)
- Ó¦Öú: 76 (³õÖÐÉú)
- ½ð±Ò: 496.3
- É¢½ð: 69
- ºì»¨: 30
- Ìû×Ó: 1051
- ÔÚÏß: 320Сʱ
- ³æºÅ: 1246356
- ×¢²á: 2011-03-27
- רҵ: ÎÞ»ú·Ç½ðÊô»ù¸´ºÏ²ÄÁÏ
3Â¥2013-05-14 09:51:08
huajian509
Òø³æ (СÓÐÃûÆø)
- Ó¦Öú: 1 (Ó×¶ùÔ°)
- ½ð±Ò: 331.5
- Ìû×Ó: 192
- ÔÚÏß: 79.2Сʱ
- ³æºÅ: 1628786
- ×¢²á: 2012-02-20
- ÐÔ±ð: GG
- רҵ: Á÷Ðв¡Ñ§·½·¨ÓëÎÀÉúͳ¼Æ

4Â¥2013-05-14 14:37:40
yuxue571
Ìú³æ (СÓÐÃûÆø)
- Ó¦Öú: 2 (Ó×¶ùÔ°)
- ½ð±Ò: 110.3
- É¢½ð: 20
- ºì»¨: 1
- Ìû×Ó: 58
- ÔÚÏß: 35.6Сʱ
- ³æºÅ: 1034030
- ×¢²á: 2010-06-02
- ÐÔ±ð: MM
- רҵ: ÉúÎï¼¼ÊõÒ©Îï
5Â¥2013-05-27 14:11:29
´óº£Ò»¹ÂÖÛ
ͳæ (СÓÐÃûÆø)
- Ó¦Öú: 33 (СѧÉú)
- ½ð±Ò: 173.1
- ºì»¨: 3
- Ìû×Ó: 133
- ÔÚÏß: 44.1Сʱ
- ³æºÅ: 302730
- ×¢²á: 2006-12-02
- ÐÔ±ð: GG
- רҵ: µ°°×ÖÊ×éѧ
6Â¥2013-06-09 12:52:28
| лл·ÖÏí!! |
7Â¥2013-08-01 14:17:50
|
8Â¥2013-08-20 16:11:33
| лл·ÖÏí |
9Â¥2013-10-22 09:15:03
tingzai0116
ľ³æ (ÕýʽдÊÖ)
- Ó¦Öú: 23 (СѧÉú)
- ½ð±Ò: 1896.7
- É¢½ð: 2
- ºì»¨: 3
- Ìû×Ó: 902
- ÔÚÏß: 193.6Сʱ
- ³æºÅ: 1109389
- ×¢²á: 2010-09-27
- ÐÔ±ð: MM
- רҵ: Ò©Îï·ÖÎö
10Â¥2013-10-22 09:23:37









»Ø¸´´ËÂ¥
zhaocy8903